文献速递淋巴瘤

维布妥昔单抗序贯多柔比星、长春碱和达卡巴嗪化疗治疗老年初治经典型霍奇金淋巴瘤的多中心II期研究

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
PubMed 文献 · J Clin Oncol · 2018-09-04

该多中心II期研究对60岁及以上初治霍奇金淋巴瘤患者给予两剂维布妥昔单抗(Bv)导入,后序贯6周期AVD化疗,缓解者再接受4剂Bv巩固。48例可评估患者中2年无事件生存率、无进展生存率和总生存率分别为80%、84%和93%,且基于老年评估的指标与生存强烈相关。

要点

  • 48例患者中37例(77%)完成6周期AVD,35例(73%)接受至少1剂Bv巩固。
  • 6周期AVD后总缓解率95%(40/42),完全缓解率90%(34/42)。
  • 2年无事件生存率80%、无进展生存率84%、总生存率93%。

核心结论

  • 序贯Bv-AVD方案耐受性良好,并与稳健的疗效相关。
  • 基于老年评估的指标与患者生存强烈相关。

研究设计与样本

  • 多中心II期研究,纳入60岁及以上初治霍奇金淋巴瘤患者。
  • 方案:两剂单药Bv(1.8 mg/kg,每3周一次)导入,后序贯6周期AVD化疗,缓解者再接受4剂Bv巩固。
  • 共48例患者可评估。

主要发现

  • 中位年龄69岁(范围60至88岁),63%为男性,中位ECOG体能状态评分为1,81%为III至IV期疾病,60%的国际预后评分为3至7分,中位累积疾病评定量表-老年综合评分为7分(52%为3至4级),12%在诊断时工具性日常生活活动能力丧失。
  • 48例中37例(77%)完成6周期AVD,35例(73%)接受至少1剂Bv巩固。
  • 初始Bv导入后,22例可评估患者中总缓解率为82%(18/22),完全缓解率为36%(8/22);6周期AVD后,42例可评估患者中总缓解率为95%(40/42),完全缓解率为90%(34/42)。
  • 48例中20例(42%)发生3至4级不良事件,最常见为中性粒细胞减少(44%)、发热性中性粒细胞减少和肺炎(各8%)、腹泻(6%);33%发生2级周围神经病变,多数患者可逆。
  • 意向性分析显示2年无事件生存率80%、无进展生存率84%、总生存率93%;累积疾病评定量表-老年综合评分≥10分 vs <10分的2年无进展生存率分别为45% vs 100%(P < .001);基线工具性日常生活活动能力丧失 vs 无丧失的2年无进展生存率分别为25% vs 94%(P < .001),后者在多变量分析中持续存在。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To improve the curability of older patients with newly diagnosed Hodgkin lymphoma. PATIENTS AND METHODS: We conducted a multicenter phase II study that administered brentuximab vedotin (Bv) sequentially before and after standard doxorubicin, vinblastine, and dacarbazine (AVD) for untreated patients with Hodgkin lymphoma age 60 years or older. After two lead-in doses of single-agent Bv (1.8 mg/kg once every 3 weeks), patients received six cycles of AVD chemotherapy followed by four consolidative doses of Bv in responding patients. RESULTS: Patient characteristics included median age of 69 years (range, 60 to 88 years), 63% male, median Eastern Cooperative Oncology Group performance status 1, 81% stage III to IV disease, 60% International Prognostic Score 3 to 7, median Cumulative Illness Rating Scale-Geriatric comorbidity score of 7 (52% grade 3 to 4); and 12% had loss of instrumental activities of daily living at diagnosis. Thirty-seven (77%) of 48 patients completed six cycles of AVD, and 35 patients (73%) received at least one Bv consolidation. Overall response and complete remission rates after initial Bv lead-in dose were 18 (82%) of 22 and 8 (36%) of 22, respectively, and 40 (95%) of 42 and 34 (90%) of 42, respectively, after six cycles of AVD among 42 response-evaluable patients. Twenty (42%) of 48 patients experienced a grade 3 to 4 adverse event, most commonly neutropenia (44%), febrile neutropenia and pneumonia (8%), or diarrhea (6%); 33% had grade 2 peripheral neuropathy, which was reversible in a majority of patients. By intent-to-treat, the 2-year event-free survival, progression-free survival, and overall survival rates were 80%, 84%, and 93%, respectively. Furthermore, 2-year progression-free survival rates for patients with a Cumulative Illness Rating Scale-Geriatric comorbidity score of ≥ 10 versus < 10 were 45% versus 100%, respectively (P < .001), and with baseline loss versus no loss of instrumental activities of daily living were 25% versus 94% (P < .001), respectively, the latter persisting on multivariable analyses. CONCLUSION: Altogether, sequential Bv-AVD was well tolerated and was associated with robust outcomes. Furthermore, geriatric-based measures were strongly associated with patient survival.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Evens AM, Advani RH, Helenowski IB, et al. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. J Clin Oncol. 2018. PMID: 30179569. doi:10.1200/JCO.2018.79.0139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。